Highlights
The global Semi-Solid Dosage Form market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Semi-Solid Dosage Form is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Semi-Solid Dosage Form is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Semi-Solid Dosage Form include Johnson & Johnson, Merck & Co, Bayer AG, Hisamitsu Pharmaceutical, Glenmark Pharmaceuticals, Cipla Ltd, Nestl茅 SA, Novartis AG and GlaxoSmithKline plc, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Semi-Solid Dosage Form, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Semi-Solid Dosage Form.
The Semi-Solid Dosage Form market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Semi-Solid Dosage Form market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Semi-Solid Dosage Form manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Johnson & Johnson
Merck & Co
Bayer AG
Hisamitsu Pharmaceutical
Glenmark Pharmaceuticals
Cipla Ltd
Nestl茅 SA
Novartis AG
GlaxoSmithKline plc
Bausch Health Companies
Allergan plc
Biofrontera, Inc.
Crown Laboratories Inc.
Akorn Inc. (US)
Ingenus Pharmaceuticals
Sun Pharmaceuticals
Crescita Therapeutics Inc.
Mylan N.V.
Encore Dermatology, Inc.
LEO Pharma
Almirall, S.A
Aclaris Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd.
Teligent Pharma
Perrigo Pharma
Segment by Type
Ointments
Gels
Others
Segment by Application
Skin
Nasal Cavity
Vaginal Cavity
Rectal Cavity
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Semi-Solid Dosage Form manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Semi-Solid Dosage Form in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Semi-Solid Dosage Form Market Overview
1.1 Product Overview and Scope of Semi-Solid Dosage Form
1.2 Semi-Solid Dosage Form Segment by Type
1.2.1 Global Semi-Solid Dosage Form Market Value Comparison by Type (2023-2029)
1.2.2 Ointments
1.2.3 Gels
1.2.4 Others
1.3 Semi-Solid Dosage Form Segment by Application
1.3.1 Global Semi-Solid Dosage Form Market Value by Application: (2023-2029)
1.3.2 Skin
1.3.3 Nasal Cavity
1.3.4 Vaginal Cavity
1.3.5 Rectal Cavity
1.3.6 Others
1.4 Global Semi-Solid Dosage Form Market Size Estimates and Forecasts
1.4.1 Global Semi-Solid Dosage Form Revenue 2018-2029
1.4.2 Global Semi-Solid Dosage Form Sales 2018-2029
1.4.3 Global Semi-Solid Dosage Form Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Semi-Solid Dosage Form Market Competition by Manufacturers
2.1 Global Semi-Solid Dosage Form Sales Market Share by Manufacturers (2018-2023)
2.2 Global Semi-Solid Dosage Form Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Semi-Solid Dosage Form Average Price by Manufacturers (2018-2023)
2.4 Global Semi-Solid Dosage Form Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Semi-Solid Dosage Form, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Semi-Solid Dosage Form, Product Type & Application
2.7 Semi-Solid Dosage Form Market Competitive Situation and Trends
2.7.1 Semi-Solid Dosage Form Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Semi-Solid Dosage Form Players Market Share by Revenue
2.7.3 Global Semi-Solid Dosage Form Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Semi-Solid Dosage Form Retrospective Market Scenario by Region
3.1 Global Semi-Solid Dosage Form Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Semi-Solid Dosage Form Global Semi-Solid Dosage Form Sales by Region: 2018-2029
3.2.1 Global Semi-Solid Dosage Form Sales by Region: 2018-2023
3.2.2 Global Semi-Solid Dosage Form Sales by Region: 2024-2029
3.3 Global Semi-Solid Dosage Form Global Semi-Solid Dosage Form Revenue by Region: 2018-2029
3.3.1 Global Semi-Solid Dosage Form Revenue by Region: 2018-2023
3.3.2 Global Semi-Solid Dosage Form Revenue by Region: 2024-2029
3.4 North America Semi-Solid Dosage Form Market Facts & Figures by Country
3.4.1 North America Semi-Solid Dosage Form Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Semi-Solid Dosage Form Sales by Country (2018-2029)
3.4.3 North America Semi-Solid Dosage Form Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Semi-Solid Dosage Form Market Facts & Figures by Country
3.5.1 Europe Semi-Solid Dosage Form Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Semi-Solid Dosage Form Sales by Country (2018-2029)
3.5.3 Europe Semi-Solid Dosage Form Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Semi-Solid Dosage Form Market Facts & Figures by Country
3.6.1 Asia Pacific Semi-Solid Dosage Form Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Semi-Solid Dosage Form Sales by Country (2018-2029)
3.6.3 Asia Pacific Semi-Solid Dosage Form Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Semi-Solid Dosage Form Market Facts & Figures by Country
3.7.1 Latin America Semi-Solid Dosage Form Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Semi-Solid Dosage Form Sales by Country (2018-2029)
3.7.3 Latin America Semi-Solid Dosage Form Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Semi-Solid Dosage Form Market Facts & Figures by Country
3.8.1 Middle East and Africa Semi-Solid Dosage Form Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Semi-Solid Dosage Form Sales by Country (2018-2029)
3.8.3 Middle East and Africa Semi-Solid Dosage Form Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Semi-Solid Dosage Form Sales by Type (2018-2029)
4.1.1 Global Semi-Solid Dosage Form Sales by Type (2018-2023)
4.1.2 Global Semi-Solid Dosage Form Sales by Type (2024-2029)
4.1.3 Global Semi-Solid Dosage Form Sales Market Share by Type (2018-2029)
4.2 Global Semi-Solid Dosage Form Revenue by Type (2018-2029)
4.2.1 Global Semi-Solid Dosage Form Revenue by Type (2018-2023)
4.2.2 Global Semi-Solid Dosage Form Revenue by Type (2024-2029)
4.2.3 Global Semi-Solid Dosage Form Revenue Market Share by Type (2018-2029)
4.3 Global Semi-Solid Dosage Form Price by Type (2018-2029)
5 Segment by Application
5.1 Global Semi-Solid Dosage Form Sales by Application (2018-2029)
5.1.1 Global Semi-Solid Dosage Form Sales by Application (2018-2023)
5.1.2 Global Semi-Solid Dosage Form Sales by Application (2024-2029)
5.1.3 Global Semi-Solid Dosage Form Sales Market Share by Application (2018-2029)
5.2 Global Semi-Solid Dosage Form Revenue by Application (2018-2029)
5.2.1 Global Semi-Solid Dosage Form Revenue by Application (2018-2023)
5.2.2 Global Semi-Solid Dosage Form Revenue by Application (2024-2029)
5.2.3 Global Semi-Solid Dosage Form Revenue Market Share by Application (2018-2029)
5.3 Global Semi-Solid Dosage Form Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Corporation Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Johnson & Johnson Semi-Solid Dosage Form Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Merck & Co
6.2.1 Merck & Co Corporation Information
6.2.2 Merck & Co Description and Business Overview
6.2.3 Merck & Co Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Merck & Co Semi-Solid Dosage Form Product Portfolio
6.2.5 Merck & Co Recent Developments/Updates
6.3 Bayer AG
6.3.1 Bayer AG Corporation Information
6.3.2 Bayer AG Description and Business Overview
6.3.3 Bayer AG Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Bayer AG Semi-Solid Dosage Form Product Portfolio
6.3.5 Bayer AG Recent Developments/Updates
6.4 Hisamitsu Pharmaceutical
6.4.1 Hisamitsu Pharmaceutical Corporation Information
6.4.2 Hisamitsu Pharmaceutical Description and Business Overview
6.4.3 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Product Portfolio
6.4.5 Hisamitsu Pharmaceutical Recent Developments/Updates
6.5 Glenmark Pharmaceuticals
6.5.1 Glenmark Pharmaceuticals Corporation Information
6.5.2 Glenmark Pharmaceuticals Description and Business Overview
6.5.3 Glenmark Pharmaceuticals Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Glenmark Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
6.5.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.6 Cipla Ltd
6.6.1 Cipla Ltd Corporation Information
6.6.2 Cipla Ltd Description and Business Overview
6.6.3 Cipla Ltd Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Cipla Ltd Semi-Solid Dosage Form Product Portfolio
6.6.5 Cipla Ltd Recent Developments/Updates
6.7 Nestl茅 SA
6.6.1 Nestl茅 SA Corporation Information
6.6.2 Nestl茅 SA Description and Business Overview
6.6.3 Nestl茅 SA Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Nestl茅 SA Semi-Solid Dosage Form Product Portfolio
6.7.5 Nestl茅 SA Recent Developments/Updates
6.8 Novartis AG
6.8.1 Novartis AG Corporation Information
6.8.2 Novartis AG Description and Business Overview
6.8.3 Novartis AG Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Novartis AG Semi-Solid Dosage Form Product Portfolio
6.8.5 Novartis AG Recent Developments/Updates
6.9 GlaxoSmithKline plc
6.9.1 GlaxoSmithKline plc Corporation Information
6.9.2 GlaxoSmithKline plc Description and Business Overview
6.9.3 GlaxoSmithKline plc Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.9.4 GlaxoSmithKline plc Semi-Solid Dosage Form Product Portfolio
6.9.5 GlaxoSmithKline plc Recent Developments/Updates
6.10 Bausch Health Companies
6.10.1 Bausch Health Companies Corporation Information
6.10.2 Bausch Health Companies Description and Business Overview
6.10.3 Bausch Health Companies Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Bausch Health Companies Semi-Solid Dosage Form Product Portfolio
6.10.5 Bausch Health Companies Recent Developments/Updates
6.11 Allergan plc
6.11.1 Allergan plc Corporation Information
6.11.2 Allergan plc Semi-Solid Dosage Form Description and Business Overview
6.11.3 Allergan plc Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Allergan plc Semi-Solid Dosage Form Product Portfolio
6.11.5 Allergan plc Recent Developments/Updates
6.12 Biofrontera, Inc.
6.12.1 Biofrontera, Inc. Corporation Information
6.12.2 Biofrontera, Inc. Semi-Solid Dosage Form Description and Business Overview
6.12.3 Biofrontera, Inc. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Biofrontera, Inc. Semi-Solid Dosage Form Product Portfolio
6.12.5 Biofrontera, Inc. Recent Developments/Updates
6.13 Crown Laboratories Inc.
6.13.1 Crown Laboratories Inc. Corporation Information
6.13.2 Crown Laboratories Inc. Semi-Solid Dosage Form Description and Business Overview
6.13.3 Crown Laboratories Inc. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Crown Laboratories Inc. Semi-Solid Dosage Form Product Portfolio
6.13.5 Crown Laboratories Inc. Recent Developments/Updates
6.14 Akorn Inc. (US)
6.14.1 Akorn Inc. (US) Corporation Information
6.14.2 Akorn Inc. (US) Semi-Solid Dosage Form Description and Business Overview
6.14.3 Akorn Inc. (US) Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Akorn Inc. (US) Semi-Solid Dosage Form Product Portfolio
6.14.5 Akorn Inc. (US) Recent Developments/Updates
6.15 Ingenus Pharmaceuticals
6.15.1 Ingenus Pharmaceuticals Corporation Information
6.15.2 Ingenus Pharmaceuticals Semi-Solid Dosage Form Description and Business Overview
6.15.3 Ingenus Pharmaceuticals Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Ingenus Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
6.15.5 Ingenus Pharmaceuticals Recent Developments/Updates
6.16 Sun Pharmaceuticals
6.16.1 Sun Pharmaceuticals Corporation Information
6.16.2 Sun Pharmaceuticals Semi-Solid Dosage Form Description and Business Overview
6.16.3 Sun Pharmaceuticals Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Sun Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
6.16.5 Sun Pharmaceuticals Recent Developments/Updates
6.17 Crescita Therapeutics Inc.
6.17.1 Crescita Therapeutics Inc. Corporation Information
6.17.2 Crescita Therapeutics Inc. Semi-Solid Dosage Form Description and Business Overview
6.17.3 Crescita Therapeutics Inc. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Crescita Therapeutics Inc. Semi-Solid Dosage Form Product Portfolio
6.17.5 Crescita Therapeutics Inc. Recent Developments/Updates
6.18 Mylan N.V.
6.18.1 Mylan N.V. Corporation Information
6.18.2 Mylan N.V. Semi-Solid Dosage Form Description and Business Overview
6.18.3 Mylan N.V. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Mylan N.V. Semi-Solid Dosage Form Product Portfolio
6.18.5 Mylan N.V. Recent Developments/Updates
6.19 Encore Dermatology, Inc.
6.19.1 Encore Dermatology, Inc. Corporation Information
6.19.2 Encore Dermatology, Inc. Semi-Solid Dosage Form Description and Business Overview
6.19.3 Encore Dermatology, Inc. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Encore Dermatology, Inc. Semi-Solid Dosage Form Product Portfolio
6.19.5 Encore Dermatology, Inc. Recent Developments/Updates
6.20 LEO Pharma
6.20.1 LEO Pharma Corporation Information
6.20.2 LEO Pharma Semi-Solid Dosage Form Description and Business Overview
6.20.3 LEO Pharma Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.20.4 LEO Pharma Semi-Solid Dosage Form Product Portfolio
6.20.5 LEO Pharma Recent Developments/Updates
6.21 Almirall, S.A
6.21.1 Almirall, S.A Corporation Information
6.21.2 Almirall, S.A Semi-Solid Dosage Form Description and Business Overview
6.21.3 Almirall, S.A Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Almirall, S.A Semi-Solid Dosage Form Product Portfolio
6.21.5 Almirall, S.A Recent Developments/Updates
6.22 Aclaris Therapeutics, Inc.
6.22.1 Aclaris Therapeutics, Inc. Corporation Information
6.22.2 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Description and Business Overview
6.22.3 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Product Portfolio
6.22.5 Aclaris Therapeutics, Inc. Recent Developments/Updates
6.23 Taro Pharmaceutical Industries Ltd.
6.23.1 Taro Pharmaceutical Industries Ltd. Corporation Information
6.23.2 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Description and Business Overview
6.23.3 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Product Portfolio
6.23.5 Taro Pharmaceutical Industries Ltd. Recent Developments/Updates
6.24 Teligent Pharma
6.24.1 Teligent Pharma Corporation Information
6.24.2 Teligent Pharma Semi-Solid Dosage Form Description and Business Overview
6.24.3 Teligent Pharma Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Teligent Pharma Semi-Solid Dosage Form Product Portfolio
6.24.5 Teligent Pharma Recent Developments/Updates
6.25 Perrigo Pharma
6.25.1 Perrigo Pharma Corporation Information
6.25.2 Perrigo Pharma Semi-Solid Dosage Form Description and Business Overview
6.25.3 Perrigo Pharma Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Perrigo Pharma Semi-Solid Dosage Form Product Portfolio
6.25.5 Perrigo Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Semi-Solid Dosage Form Industry Chain Analysis
7.2 Semi-Solid Dosage Form Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Semi-Solid Dosage Form Production Mode & Process
7.4 Semi-Solid Dosage Form Sales and Marketing
7.4.1 Semi-Solid Dosage Form Sales Channels
7.4.2 Semi-Solid Dosage Form Distributors
7.5 Semi-Solid Dosage Form Customers
8 Semi-Solid Dosage Form Market Dynamics
8.1 Semi-Solid Dosage Form Industry Trends
8.2 Semi-Solid Dosage Form Market Drivers
8.3 Semi-Solid Dosage Form Market Challenges
8.4 Semi-Solid Dosage Form Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Johnson & Johnson
Merck & Co
Bayer AG
Hisamitsu Pharmaceutical
Glenmark Pharmaceuticals
Cipla Ltd
Nestl茅 SA
Novartis AG
GlaxoSmithKline plc
Bausch Health Companies
Allergan plc
Biofrontera, Inc.
Crown Laboratories Inc.
Akorn Inc. (US)
Ingenus Pharmaceuticals
Sun Pharmaceuticals
Crescita Therapeutics Inc.
Mylan N.V.
Encore Dermatology, Inc.
LEO Pharma
Almirall, S.A
Aclaris Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd.
Teligent Pharma
Perrigo Pharma
听
听
*If Applicable.